Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Wave Life Sciences Ltd.NASDAQ: WVE

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt remains negative

Q1 FY2026 short-term debt was $0, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Short-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Short-term Debt vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
  • Short-term debt amounts to 0.0% of total assets for WVE, versus a peer median of 0.0%.
WVE Competitors
Short-term Debt for WVE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IONSIonis Pharmaceuticals, Inc.Sep 2026$138.19M USD-78.1%+291.8%4.7%
ARWRArrowhead Pharmaceuticals, Inc.Sep 2026$40M USD+0.0%+55.9%2.3%
PRQRProQR Therapeutics N.V.Mar 2026€4.62M EUR-1.9%+21.1%4.7%
STOKStoke Therapeutics, Inc.Mar 2026$2.43M USD——0.5%
WVEWave Life Sciences Ltd.Mar 2026$0 USD——0.0%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$0 USD——0.0%
SRPTSarepta Therapeutics, Inc.Mar 2026$0 USD——0.0%
NTLAIntellia Therapeutics, Inc.Mar 2026$0 USD——0.0%
SLNSilence Therapeutics plcMar 2026$0 USD——0.0%
BNTCBenitec Biopharma Inc.Mar 2026$0 USD——0.0%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$0 USD——0.0%
Peer median (excluding WVE) —-1.9%+55.9%0.0%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents150.56M88.5M200.35M302.08M602.07M
Short-term Investments00000
Net Receivables0021.09M1.42M1.28M
Inventory00000
Other Current Assets5.42M2.11M4.02M7.35M3.08M
Total Current Assets162.56M98.54M235.37M320.39M614.81M
Property, Plant & Equipment (Net)40.64M44.13M35.72M28M19.86M
Goodwill00000
Intangible Assets00000
Long-term Investments00003.81M
Tax Assets00000
Other Non-current Assets3.8M3.72M3.86M3.82M16K
Total Non-current Assets44.44M47.85M39.58M31.81M23.69M
Total Assets207.01M146.39M274.95M352.21M638.5M
Account Payables7.28M16.92M12.84M16.26M15.7M
Short-term Debt00000
Tax Payables00000
Deferred Revenue37.1M31.56M150.06M65.97M44.44M
Other Current Liabilities10.18M12.29M14.07M15.36M18.08M
Total Current Liabilities64.2M71.52M186.44M110.95M95.07M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)77.48M79.77M15.6M6.1M7.8M
Other Non-current Liabilities7.87M8.06M7.87M7.87M0
Total Non-current Liabilities110.31M119.96M48.88M31.74M17.2M
Total Liabilities174.51M191.48M235.32M142.69M112.27M
Common Stock749.85M802.83M935.37M1.18B1.62B
Retained Earnings(805.51M)(967.34M)(1.02B)(1.12B)(1.33B)
Accumulated OCI181K(29K)(124K)(262K)(250K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity32.5M(45.09M)39.63M209.52M526.23M
Total Debt29.92M37.61M32.12M25.4M17.77M
Net Debt(120.65M)(50.88M)(168.23M)(276.67M)(584.3M)

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.